Mark Zimmerman, MD, discusses controversies related to categorizing severity and identifying optimal treatment of depression.
Transition from a once-monthly formulation of a long-acting, injectable paliperidone palmitate to a once-every-3-month formulation treatment regimen in patients with schizophrenia demonstrated increased adherence to antipsychotic medication.
At 6 weeks of treatment, severely ill patients treated with adjunctive brexpiprazole had a greater reduction in PANSS total scores and CGI-S scores compared with those receiving placebo.
Patients with PTSD should consider concurrent treatment with evidence-based psychotherapy to maximize their chances for meaningful improvement.
Younger individuals may be more at risk for death by suicide, and in older patients, elevated levels of metabolic syndrome may lead to higher rates of death from heart disease.
Investigators sought to examine the short- and long-term antidepressant and antisuicidal effects of repeated-dose ketamine augmentation in patients with treatment-resistant depression.
Researchers found a limited association between the ranking of a physician’s medical school and patient mortality or readmission rates.
Existing 2-dimensional models are likely not sufficient to capture the complexity of negative symptoms in schizophrenia.
The authors argue that these findings suggest that reducing shame among veterans with post-traumatic stress disorder may reduce the risk for suicide.